Journey Medical (NASDAQ:DERM) Rating Increased to Strong-Buy at Roth Capital

Journey Medical (NASDAQ:DERM) was upgraded by analysts at Roth Capital to a “strong-buy” rating in a research report issued on Friday, Zacks.com reports.

Separately, Roth Mkm assumed coverage on Journey Medical in a report on Friday. They set a “buy” rating and a $11.00 price target on the stock.

Journey Medical Stock Up 9.7 %

Journey Medical stock opened at $5.64 on Friday. The stock has a fifty day simple moving average of $4.20. Journey Medical has a twelve month low of $1.52 and a twelve month high of $8.11. The company has a market capitalization of $112.86 million, a P/E ratio of -18.19 and a beta of 0.79. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.21 and a quick ratio of 0.94.

Journey Medical (NASDAQ:DERM) last issued its earnings results on Monday, May 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.27). The company had revenue of $13.03 million for the quarter, compared to analysts’ expectations of $14.91 million. Journey Medical had a negative net margin of 5.20% and a negative return on equity of 32.83%. As a group, equities analysts expect that Journey Medical will post -1.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of DERM. Acadian Asset Management LLC increased its holdings in shares of Journey Medical by 687.5% during the first quarter. Acadian Asset Management LLC now owns 222,663 shares of the company’s stock valued at $817,000 after acquiring an additional 194,389 shares in the last quarter. Heron Bay Capital Management bought a new stake in Journey Medical during the 1st quarter valued at about $124,000. Finally, Nwam LLC purchased a new position in Journey Medical in the first quarter worth about $41,000. 7.25% of the stock is currently owned by institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.